Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Asset Writedowns and Impairment (2020 - 2021)

VYNE Therapeutics (VYNE) has disclosed Asset Writedowns and Impairment for 1 consecutive years, with $1.6 million as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Asset Writedowns and Impairment changed N/A year-over-year to $1.6 million, compared with a TTM value of $1.6 million through Dec 2021, changed N/A, and an annual FY2021 reading of $1.6 million, down 97.06% over the prior year.
  • Asset Writedowns and Impairment was $1.6 million for Q4 2021 at VYNE Therapeutics.
  • Across five years, Asset Writedowns and Impairment topped out at $1.6 million in Q4 2021 and bottomed at $1.6 million in Q4 2021.